Aspira Women's Health Inc.
AWHL evidence brief
What we can confirm
- BioSniper Score:
- 5.5 / 10
- Market Cap:
- $14.0M
- Lead Asset:
- ova1 (Approved)
What it means
What to watch
Prepared research question
What matters most for AWHL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AWHL
Aspira Women's Health Inc. (AWHL) is a women's health diagnostics company focused on ovarian cancer and endometriosis testing, operating with limited cash and a negative shareholders' equity as of mid-2026.
Key risk: Insufficient liquidity
BioSniper Score
Based on 4 of 6 signals
Market Cap
$14.0M
Cash Runway
—
Lead Asset
ova1 (Approved)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for Aspira Women's Health Inc..
Aspira Women's Health Inc. (AWHL) is a women's health diagnostics company focused on ovarian cancer and endometriosis testing, operating with limited cash and a negative shareholders' equity as of mid-2026.
- Cash and cash equivalents were $0.5M as of 2026-06-30 [sec].
- Net income was -$2.4M for the period ending 2026-06-30 [sec].
- Shareholders' equity was -$7.3M as of 2026-06-30 [sec].
- The company's Ova1Plus test is positioned as diagnostically superior to CA-125 for ovarian cancer risk assessment [sec_mda · as of 2026-08-14].
- ENDOinform is a key pipeline program for endometriosis identification using multi-omic biomarkers [sec_mda · as of 2026-08-14].
What works
- The company has a pipeline of new gynecologic diagnostic products, including ENDOinform for endometriosis, developed with academic partners like Dana-Farber Cancer Institute [sec_mda · as of 2026-08-14].
- Management reported reducing cash used in operations by 40% and decreasing net loss by 51%, indicating progress toward cost efficiency [sec_mda · as of 2026-04-01].
- Aspira plans to expand its addressable market to over 10 million women by broadening focus to other gynecologic diseases [sec_mda · as of 2026-04-01].
What to weigh
- Cash and cash equivalents were only $0.5M as of 2026-06-30, with current liabilities of $5.3M and a working capital deficit of $2.5M [sec_mda · as of 2026-08-14].
- The company stated it does not believe existing cash and cash flows will be sufficient to meet working capital and capital expenditure needs for the next twelve months [sec_mda · as of 2026-04-01].
- Shareholders' equity was negative $7.3M as of 2026-06-30, indicating accumulated losses exceed equity [sec].
- There is no assurance of achieving or sustaining profitability or positive cash flow from operations [sec_mda · as of 2026-08-14].
From the filings
Quoted directly from source documents.
Cash position as of June 30, 2026
“As of June 30, 2026, we had $477,000 in cash and cash equivalents”
SEC MD&A · August 14, 2026
Working capital deficit as of June 30, 2026
“a working capital deficit of $2,542,000”
SEC MD&A · August 14, 2026
ENDOinform is a key pipeline development focus
“ENDOinform, a key pipeline development focus, is amulti-omic biomarkertest program including a proprietary combination of serum proteins, miRNAs and clinical metadata for the identification of endometriosis.”
SEC MD&A · August 14, 2026
Risks & what to watch (4)›
Key risks
- Insufficient liquidity — Cash of $0.5M as of 2026-06-30 may not cover near-term obligations; working capital deficit of $2.5M [sec_mda · as of 2026-08-14].
- Negative equity — Shareholders' equity of -$7.3M as of 2026-06-30 signals accumulated losses exceed capital [sec].
- Profitability uncertainty — No assurance of achieving or sustaining profitability or positive cash flow from operations [sec_mda · as of 2026-08-14].
- Dependence on product revenue — Revenue from products is the only material recurring cash source for the remainder of 2026 [sec_mda · as of 2026-08-14].
What to watch
- Cash runway and ability to raise additional capital given the $0.5M cash balance and negative equity [sec_mda · as of 2026-08-14].
- Commercial adoption of Ova1Plus and its impact on revenue growth [sec_mda · as of 2026-08-14].
- Progress of the ENDOinform pipeline program toward commercialization [sec_mda · as of 2026-08-14].
- Ability to sustain cost reduction trends (40% reduction in cash used in operations) [sec_mda · as of 2026-04-01].
Sources: SEC MD&A · Generated October 13, 2026 · How we verify sources →
Run Aspira Women's Health Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Aspira Women's Health Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
Net income -$2M
Lead: Approved
1 candidate
No upcoming catalysts tracked
1 buy · 0 sells (180d)
Pipeline
Financials
Short Interest
as of May 20, 2026- % of float
- 0.8%
- Days to cover
- 0.0
- Shares short
- 252,929
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AWHL short interestGovernance
Frequently asked questions
What is the AI investment thesis for Aspira Women's Health Inc.?
Aspira Women's Health Inc. (AWHL) is a women's health diagnostics company focused on ovarian cancer and endometriosis testing, operating with limited cash and a negative shareholders' equity as of mid-2026.
What is Aspira Women's Health Inc.'s lead drug candidate?
Aspira Women's Health Inc.'s most advanced tracked candidate is ova1 (Approved) for likelihood of malignancy in women with an ovarian adnexal mass.
Who is the CEO of Aspira Women's Health Inc.?
Mr. Michael Buhle is the chief executive officer of Aspira Women's Health Inc. (AWHL).
Where is Aspira Women's Health Inc. headquartered?
Aspira Women's Health Inc. (AWHL) is headquartered in Austin, TX, United States.
What therapeutic areas does Aspira Women's Health Inc. focus on?
Aspira Women's Health Inc. develops therapies across Oncology, Pain, Reproductive.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.